Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634948 | 0.78 | LMNA (0.36) | LMNASMN1; SMN2ATM | |
| SCHEMBL23278023 | 0.76 | ATM (0.42) | LMNASMN1; SMN2ATM | |
| SCHEMBL3635465 | 0.76 | L3MBTL1 (0.37) | LMNASMN1; SMN2ATM | |
| SCHEMBL4404464 | 0.74 | CYP1A2 (0.41) | LMNASMN1; SMN2ATM | |
| Hydrochloric Acid SCHEMBL9698155 | 0.74 | L3MBTL1 (0.35) | LMNASMN1; SMN2ATM | |
| SCHEMBL1088468 | 0.73 | SIGMAR1 (0.37) | LMNASMN1; SMN2ATM | |
| SCHEMBL2862694 | 0.73 | SMN1; SMN2 (0.45) | SMN1; SMN2 | |
| SCHEMBL18123290 | 0.73 | LMNA (0.37) | LMNASMN1; SMN2ATM | |
| SCHEMBL3314582 | 0.73 | LMNA (0.37) | LMNASMN1; SMN2ATM | |
| Hydrochloric Acid SCHEMBL189931 | 0.71 | HPGD (0.39) | LMNASMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298009-A1 | Fused Pyrazole Derivatives As Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-10-18 | — | — | US | disclosed |
| US-20180273525-A1 | Fused Pyridine Derivatives As Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-09-27 | — | — | US | disclosed |
| EP-3356365-A1 | FUSED PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SPRL (BE) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356367-A1 | FUSED PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SPRL (BE) | 2018-08-08 | — | — | EP | disclosed |
| EP-2017278-B1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD KK (JP) | 2016-11-02 | — | — | EP | disclosed |
| EP-2376493-B1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2016-10-05 | — | — | EP | disclosed |
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD KK (JP) | 2014-10-09 | — | — | US | disclosed |
| EP-2499129-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-07-30 | — | — | EP | disclosed |
| US-8791125-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20110243891-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD K.K. | 2011-10-06 | — | — | US | disclosed |
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | SAGARA TAKESHI | 2011-08-04 | — | — | US | disclosed |
| WO-2011058112-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2011-05-19 | — | — | WO | disclosed |
| US-7935708-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7834019-B2 | Substituted pyrazolo[3,4-d]pyrimidinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| WO-2010067886-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067888-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | MERCK SHARP & DOHME LLC | 2010-03-11 | — | — | US | disclosed |
| EP-2017278-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | LMNA 3734/4885SMN1; SMN2 3943/4885ATM 453/4885 |
| US-20180273525-A1 | Fused Pyridine Derivatives As Kinase Inhibitors | PI4KA, PI4KB, PI4K2B | LMNA 4404/4885SMN1; SMN2 4222/4885ATM 1062/4885 |
| US-20180298009-A1 | Fused Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PI4K2B, PI4KB | LMNA 4839/4885SMN1; SMN2 4769/4885ATM 1030/4885 |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | WEE1, WEE2, GRK3 | LMNA 3734/4885SMN1; SMN2 3943/4885ATM 453/4885 |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | WEE1, WEE2, GRK3 | LMNA 3734/4885SMN1; SMN2 3943/4885ATM 453/4885 |
| US-20110243891-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | WEE2, WEE1, RPS6KA1 | LMNA 3365/4885SMN1; SMN2 4459/4885ATM 303/4885 |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | LMNA 3734/4885SMN1; SMN2 3943/4885ATM 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.